A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Registration Number
- NCT00503477
- Lead Sponsor
- AstraZeneca
- Brief Summary
A Phase I open label dose escalation study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients in Japan with advanced solid malignancies. In addition there will be an expanded cohort multi-centre study phase with NSCLC patient and CRC patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- advanced solid tumors
- life expectancy is 12 weeks or longer
Read More
Exclusion Criteria
- patient with uncontrolled brain metastases
- patient with inappropriate laboratory test values
- patient with poorly controlled hypertension
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety and tolerability Assessed at each visit for 4 weeks
- Secondary Outcome Measures
Name Time Method efficacy, PK Assessed at each visit for 4 weeks
Trial Locations
- Locations (1)
Research Site
🇯🇵Tokyo, Japan